2025-10-17T07:41:23-05:00 2025-06-30 593040705 RIVERO GORDIMER & COMPANY PA 201 N FRANKLIN ST SUITE 2200 TAMPA FL 33602 990 2024-07-01 593097333 NATIONAL PEDIATRIC CANCER FOUNDATION INC NATI 8132690955 5550 WEST EXECUTIVE DRIVE SUITE 20 TAMPA FL 33609 DAVID FRAZER CHIEF EXECUTIVE OFFICER 8132690955 2025-10-09 1 0 SAM A LAZZARA P01342929 8138757774 2024 2025-03-06 01:10:19Z DAVID FRAZER 5550 WEST EXECUTIVE DRIVE SUITE 200 TAMPA FL 33609 7238881 0 X WWW.NATIONALPCF.ORG X 1991 FL THE NPCF IS DEDICATED TO FUNDING RESEARCH TO ELIMINATE CHILDHOOD CANCER. 22 22 21 300 0 0 4516155 4219467 0 0 161711 87081 332222 143421 5010088 4449969 2820170 3441620 0 0 1589140 1685577 0 0 356020 665731 595853 5075041 5723050 -64953 -1273081 7031609 6202847 930873 1059559 6100736 5143288 X NATIONAL PEDIATRIC CANCER FOUNDATION (NPCF) IS A NONPROFIT ORGANIZATION DEDICATED TO FUNDING RESEARCH TO ELIMINATE CHILDHOOD CANCER. OUR FOCUS IS TO FUND RESEARCH TO FIND LESS TOXIC, MORE TARGETED THERAPIES BY PARTNERING WITH LEADING HOSPITALS NATIONWIDE. 0 0 5120886 3441620 THE NATIONAL PEDIATRIC CANCER FOUNDATION FUNDS PEDIATRIC CANCER RESEARCH WITH THE GOAL OF LEADING TO THE TREATMENT AND ELIMINATION OF PEDIATRIC CANCER WORLDWIDE.WE ACCOMPLISH OUR MISSION THROUGH OUR RESEARCH INITIATIVE, THE SUNSHINE PROJECT, AN INNOVATIVE COLLABORATION OF 40 HOSPITALS NATIONWIDE. THIS COLLABORATIVE RESEARCH MODEL IS UNIQUE AND EFFECTIVE IN ACCELERATING THE DEVELOPMENT OF NEW TREATMENTS AGAINST CHILDHOOD CANCER.SEE SCHEDULE O FOR FURTHER PROGRAM SERVICE ACCOMPLISHMENTS.IN DEVELOPING THIS COLLABORATION, THE FOUNDATION HAS BROUGHT TOGETHER SOME OF THE COUNTRY'S LEADING INVESTIGATORS AND INSTITUTIONS TO DRIVE THE PROCESS OF FINDING A CURE. INVESTIGATORS ARE PERFORMING THREE VITAL PHASES OF RESEARCH SIMULTANEOUSLY: BASIC SCIENCE, TRANSLATIONAL RESEARCH AND CLINICAL TRIALS. THESE MAJOR RESEARCH COMPONENTS NOT ONLY ALLOW DOCTORS TO IDENTIFY NEW AGENTS IN FIGHTING CANCER, BUT ALSO HELP RESEARCHERS TO UNDERSTAND THE CANCER CELLS RESPONSE TO THE DRUG. THE NATIONAL PEDIATRIC CANCER FOUNDATION IS MAKING GREAT STRIDES IN ITS MISSION TO FIND A CURE FOR CHILDHOOD CANCER.CURRENT INITIATIVES OF THE SUNSHINE PROJECT ARE AS FOLLOWS:SARCOMA TRIALS (OSTEOSARCOMA, RHABDOMYOSARCOMA, EWING SARCOMA, NON-RHABDOMYOSARCOMA); BRAIN CANCER TRIALS (MEDULLOBLASTOMA, HIGH-GRADE GLIOMA); SOLID STATE TUMORS1. EVOLUTIONARY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA - METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA (RMS) HAVE A POOR OUTCOME WHICH IS WORSENED WITH ADDITIONAL RISK FACTORS COMMONLY CALLED THE OBERLIN CRITERIA. PATIENTS THAT MEET ALL 4 OBERLIN CRITERIA HAVE AN EVENT FREE SURVIVAL (EFS) OF LESS THAN 20% AT 2 YEARS. ALL THERAPEUTIC ARMS ON THIS STUDY ARE DESIGNED TO MEET THE SAME PRIMARY AIM OF IMPROVING THE 3-YEAR EVENT FREE SURVIVAL FROM 6% TO 35% FOR THESE PATIENTS. 2. BLOOD BASED BIOMARKERS FOR MINIMAL RESIDUAL DISEASE DETECTION IN PEDIATRIC SARCOMAS - THE PURPOSE OF THIS STUDY IS TO SEE IF DETECTING CELL-FREE PLASMA TUMOR DNA (PTDNA) AND CIRCULATING TUMOR CELLS (CTC) CAN PREDICT RECURRENCE OF DISEASE IN PATIENTS WHO ARE IN RADIOGRAPHIC REMISSION 2-3 WEEKS AFTER TREATMENT. PLASMA TUMOR DNA (PTDNA) IS FREE FLOATING DNA FROM THE TUMOR FOUND IN THE BLOOD STREAM AND CIRCULATING TUMOR CELLS.3. A MULTI-INSTITUTION STUDY OF TGFB IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NK CELL INFUSIONS AS ADOPTIVE IMMUNOTHERAPY IN COMBINATION WITH GEMCITABINE AND DOCETAXEL IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC BONE AND SOFT TISSUE SARCOMAS: THE TINKS TRIAL - THE PURPOSE OF THIS TRIAL IS TO DETERMINE THE SAFETY OF THE ADDITION OF ADOPTIVE TRANSFER OF UNIVERSAL DONOR, TGFB IMPRINTED (TGFBI), EXPANDED NK CELLS TO GEMCITABINE/DOCETAXEL (GEM/DOX) FOR TREATMENT OF RELAPSED AND REFRACTORY SARCOMAS AND TO DETERMINE THE 6 MONTH PROGRESSION FREE SURVIVAL ACHIEVED WITH THIS TREATMENT.4. FEASIBILITY OF GENERATING NOVEL TRANSLATIONAL AND THERAPEUTIC STRATEGIES BASED ON A MULTICENTER, PEDIATRIC AND AYA EVOLUTIONARY TUMOR BOARD (PEDSETB) - PEDIATRIC EVOLUTIONARY TUMOR BOARD (PEDSETB) IS A MULTIDISCIPLINARY FORUM TO APPROACH AN INDIVIDUAL PATIENT'S CANCER AND PROPOSE ADDITIONAL IDEAS FOR CARE. THE PEDSETB WILL GATHER DISCIPLINES NOT OFTEN ENGAGED IN CANCER WORK AND USE INSIGHTS FROM EVOLUTION TO OPTIMALLY MODEL, RESEARCH, AND IMPACT PEDIATRIC CANCER OUTCOMES. STRATEGIES FROM PEDSETB'S PREDECESSOR HAVE BEEN INSTRUMENTAL IN THE DESIGN OF SEVERAL OF NPCF'S MOST RECENT CLINICAL TRIALS5. EVALUATION OF DIGOXIN FOR RELAPSED NON-WNT, NON-SHH MEDULLOBLASTOMA (PHASE 2 STUDY) - THIS TRIAL WILL EVALUATE THE EFFICACY OF DIGOXIN IN TREATING PATIENTS WITH RELAPSED NON-SHH, NON-WNT MEDULLOBLASTOMA AND TO DETERMINE IF DIGOXIN IMPROVES PROGRESSION FREE SURVIVAL AT 4 MONTHS AFTER INITIATION OF STUDY TREATMENT IN THIS PATIENT POPULATION. 6. METASTATIC EWING'S TRIAL TESTING SCHEDULE ENHANCEMENT TO IMPROVE OUTCOMES - THIS TRIAL WILL TEST OUR ABILITY TO ADMINISTER FREQUENTLY CHANGING CHEMOTHERAPY REGIMENS, CALLED SEQUENTIAL SECOND STRIKES, TO PATIENTS WITH WIDELY METASTATIC EWING SARCOMA TO STOP ITS DEVELOPMENT OF RESISTANCE TO CHEMOTHERAPY AND IMPROVE CURE RATES.7. RNA LIPID PARTICLES TARGETING PEDIATRIC RECURRENT INTRACRANIAL MALIGNANCIES AND OTHER SYSTEMIC SOLID TUMORS - THIS TRIAL TESTS THE SAFETY, IMMUNE EFFECTS, AND POTENTIAL EFFECTIVENESS OF RNA-LOADED LIPID NANOPARTICLES (RNA-LP) VACCINES IN PATIENTS WITH RECURRENT PEDIATRIC HIGH-GRADE GLIOMA (PHGG), A TYPE OF BRAIN CANCER, AND RECURRENT OSTEOSARCOMA (OSA), A TYPE OF BONE CANCER. 8. OPEN-LABEL, COHORT-SEQUENTIAL DOSE-ESCALATION AND DOSE-CONFIRMATION PHASE 1-2 CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF DOMATINOSTAT IN COMBINATION WITH SIROLIMUS IN ADOLESCENTS AND ADULTS WITH RELAPSED, REFRACTORY SARCOMA AND OSTEOSARCOMA - THIS TRIAL TESTS THE SAFETY AND EFFECTIVENESS OF TWO DRUGS, DOMATINOSTAT AND SIROLIMUS, USED TOGETHER IN PATIENTS WITH OSTEOSARCOMA AND OTHER SARCOMAS THAT HAVE COME BACK OR DON'T RESPOND TO OTHER TREATMENTS. 9. ENGINEERED DESTABILIZED AU RICH ELEMENTS OF C-MYC 3'UTR AS THERAPEUTICS FOR C-MYC DRIVEN PEDIATRIC CANCERS - THIS STUDY HAS IDENTIFIED A NOVEL TECHNOLOGY THAT CAN CONTROL AND DEGRADE A SPECIFIC C-MYC GENE (KNOWN AS THE MASTER REGULATOR) ACROSS MANY TYPES OF CANCERS. SINCE C-MYC IS DETECTED IN 74% OF HUMAN CANCERS, THE ABILITY TO DEGRADE AND ATTACK THIS COMMON LINK HAS THE POTENTIAL TO TRANSFORM THE TREATMENT OF CANCER. 10. TREATING LEPTOMENINGEAL SPREAD OF PEDIATRIC MEDULLOBLASTOMA WITH QUANTUM RADIOLOGY - THIS STUDY WILL USE QUANTUM MECHANICS TO PRECISELY TARGET SPECIFIC TUMOR CELLS WITHOUT HARMING NORMAL CELLS. THE METHOD USES CONVENTIONAL CLINICAL PROCEDURES IN A NOVEL COMBINATION WITHIN A WEAK MAGNETIC FIELD, AKIN TO A REFRIGERATOR MAGNET'S, SUCH THAT IF SUCCESSFUL IT COULD BE INTRODUCED INTO ANY HOSPITAL WITHOUT MAJOR INFRASTRUCTURAL, FINANCIAL OR PROCEDURAL DIFFICULT TO TREAT CHILDREN AND EVEN INFANTS WITH MEDULLOBLASTOMA, THE MOST COMMON CHILDHOOD BRAIN CANCER. 5120886 1 1 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 58 0 1 21 0 0 0 0 0 0 1 1 0 0 0 0 0 0 X 22 22 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 FL AL AK CA CO CT DC GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN TX UT VT VA WA WV WI X X X NATIONAL PEDIATRIC CANCER FOUNDATION INC 8132690955 5550 WEST EXECUTIVE DRIVE SUITE 200 TAMPA FL 33609 ALBERT SILVA CHAIRMAN OF THE BOARD 2.00 X X 0 0 0 MICHAEL LEVIN PAST CHAIR 2.00 X X 0 0 0 RICHARD HUFF VICE CHAIRMAN 2.00 X X 0 0 0 ALEX SULLIVAN VICE CHAIRMAN 2.00 X X 0 0 0 JEREMY PERSINGER TREASURER 2.00 X X 0 0 0 JOHN FITZPATRICK SECRETARY 2.00 X X 0 0 0 MICHAEL WEIGNER ASSISTANT SECRETARY 2.00 X X 0 0 0 MELISSA DUNKEL CO-FOUNDER AT LARGE 1.00 X 0 0 0 JIM BASSIL DIRECTOR 1.00 X 0 0 0 BB ABBOTT DIRECTOR 1.00 X 0 0 0 DAVID BOYINGTON DIRECTOR 1.00 X 0 0 0 CHRIS CARRERE DIRECTOR AT LARGE 1.00 X 0 0 0 CARRIE CHARLES DIRECTOR 1.00 X 0 0 0 CHAD HARROD EMERITUS 1.00 X 0 0 0 JOSEPH LAMPHIER DIRECTOR 1.00 X 0 0 0 JAY LANGFORD DIRECTOR 1.00 X 0 0 0 JEFF MAXWELL DIRECTOR AT LARGE 1.00 X 0 0 0 MARK MCHUGH DIRECTOR AT LARGE 1.00 X 0 0 0 ANGELA NORTH DIRECTOR 1.00 X 0 0 0 MARCO SCHNABL DIRECTOR AT LARGE 1.00 X 0 0 0 DAWN SILER-NIXON DIRECTOR 1.00 X 0 0 0 ASHLIE TEELING DIRECTOR 1.00 X 0 0 0 DAVID FRAZER CEO 40.00 X 210377 0 0 DAWN ZACHMAN COO 40.00 X 119939 0 0 ROBERT MARTIN CFO THRU OCTOBER 2024 40.00 X 132178 0 0 JENNIFER FINNEMORE CFO START OCTOBER 2024 40.00 X 30492 0 0 492986 0 0 3 0 1 0 0 861586 3357881 10622 4219467 129377 129377 963645 1005941 -42296 -42296 -42296 1917654 861586 1782971 134683 134683 MISCELLANEOUS REVNEUE 900099 8738 8738 8738 4449969 0 0 230502 3429303 3429303 12317 12317 492986 414454 42970 35562 1023485 860446 89208 73831 52634 44249 4588 3797 116472 97918 10152 8402 28270 28270 36032 1566 29708 4758 132228 1207 88 130933 19313 8968 5803 4542 108836 89179 12673 6984 49241 42417 3420 3404 17857 2500 3807 11550 1623 117 351 1155 28378 24984 1677 1717 52167 45961 3121 3085 31415 24845 4859 1711 ONLINE TRANSACTION FEES 44788 0 3154 41634 POSTAGE AND SHIPPING 27022 5864 656 20502 CONTRACT LABOR 12583 11070 771 742 PRINTING AND REPRODUCTI 4092 3521 336 235 2008 532 1476 5723050 5120886 246144 356020 1273888 581005 602727 32475 21455 193136 134416 1692819 178174 1510693 1514645 3750447 3050583 270970 298016 7031609 6202847 76027 126715 272704 189597 37743 647870 608148 17379 14249 930873 1059559 X 5418356 4475544 682380 667744 6100736 5143288 7031609 6202847 -1273081 315633 0 X X 0 1 X 1 0 X 4078949 3578042 3041195 3886542 4219467 18804195 4078949 3578042 3041195 3886542 4219467 18804195 1705946 17098249 958567 99773 128799 161711 129377 1478227 20282422 3534561 0.84300 0.83730 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 2347526 3916 240668 2592110 2097998 28104 221424 2347526 1904761 30479 162758 2097998 2194890 25172 -315301 1904761 1013600 883542 297748 2194890 0.88000 0.03000 0.09000 0 0 1545000 117545 1427455 147819 60629 87190 1514645 FINANCING LEASE PAYABLE 14249 14249 X 4748979 315633 11647 327280 4421699 28270 28270 4449969 5706427 11647 11647 5694780 28270 28270 5723050 PART X, LINE 2: THE FOUNDATION HAS RECEIVED A DETERMINATION OF TAX EXEMPT STATUS UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. ACCORDINGLY, NO PROVISION FOR INCOME TAXES IS REFLECTED IN THE ACCOMPANYING FINANCIAL STATEMENTS. MANAGEMENT IS NOT AWARE OF ANY ACTIVITIES THAT WOULD JEOPARDIZE THE FOUNDATION'S TAX EXEMPT STATUS. THE FOUNDATION IS NOT AWARE OF ANY TAX POSITIONS IT HAS TAKEN THAT ARE SUBJECT TO A SIGNIFICANT DEGREE OF UNCERTAINTY. TAX YEARS AFTER JUNE 30, 2021 REMAIN SUBJECT TO EXAMINATION BY TAXING AUTHORITIES. PART V, LINE 4: THE NATIONAL PEDIATRIC CANCER FOUNDATION MAINTAINS AN ENDOWMENT FUND AT THE COMMUNITY FOUNDATION OF TAMPA BAY, INC. FOR THE LONG TERM BENEFIT OF THE NATIONAL PEDIATRIC CANCER FOUNDATION. FASHION FUNDS THE CURE 1839959 726238 1113721 37500 957861 FISHING FUNDS THE CURE 563749 81345 482404 1305 429010 8 375532 54003 321529 17300 339995 2779240 861586 1917654 56105 1726866 1782971 134683 1 H LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE FOUNDATION INC 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238636 501(C)(3) 110000 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. H LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE 12902 MAGNOLIA DRIVE TAMPA FL 33612 592451713 501(C)(3) 657764 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 472209056 501(C)(3) 713110 0 FOR 43 CHALLENGE PROJECT - ENGINEERED DESTABILIZED AU RICH ELEMENTS OF C-MYC 3UTR AS THERAPEUTICS FOR C-MYC DRIVEN PEDIATRIC CANCERS AND ONE CARON META IN EWING SARCOMA TRIAL UNIVERSITY OF FLORIDA PO BOX 115500 GAINESVILLE FL 32611 596002052 501(C)(3) 64417 0 IN SUPPORT OF CLINICAL TRIAL ADVANCING INKT STUDY UNIVERSITY OF COLORADO MS F428 AMC BLDG 500 AURORA CO 80045 846000555 501(C)(3) 91654 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. CONNECTICUT CHILDREN'S MEDICAL CENTER 282 WASHINGTON ST HARTFORD CT 06106 232619869 501(C)(3) 40856 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. DUKE UNIVERSITY PO BOX 104132 DURHAM NC 27708 560532129 501(C)(3) 37118 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. VANDERBILT UNIVERSITY MEDICAL CENTER 3319 WEST END AVE SUITE 700 NASHVILLE TN 37203 352528741 501(C)(3) 37964 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. THE UNIVERSITY OF NORTH CARLINA AT CHAPEL HILL 104 AIRPORT DRIVE SUITE 2200 CHAPEL HILL NC 27599 566001393 501(C)(3) 102500 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVE CLEVELAND OH 44195 340714585 501(C)(3) 192451 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL PO BOX 781653 DETROIT MI 48278 311036372 501(C)(3) 992092 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 10889 WILSHIRE BLVD SUITE 700 LOS ANGELES CA 90095 943067788 501(C)(3) 200000 0 FOR 43 CHALLENGE PROJECT - TREATING LEPTOMENINGEAL SPREAD OF PEDIATRIC MEDULLOBLASTOMA WITH QUANTUM RADIOBIOLOGY BAYCARE ST JOSEPH'S HOSPITAL INC 2985 DREW ST CLEARWATER FL 33579 590774199 501(C)(3) 44306 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. JOHN HOPKINS UNIVERSITY 1800 ORLEANS STREET BLOOMBERG 11N BALTIMORE MD 21287 520595110 501(C)(3) 50000 0 IN SUPPORT OF CLINICAL TRIAL ADVANCING RHABDOMYOSARCOMA RESEARCH CHILDREN'S RESEARCH INSTITUTE 1 INVENTA PLACE WEST TOWER 3RD FLOOR SILVER SPRING MD 20910 521640402 501(C)(3) 95071 0 IN SUPORT OF INKT TRIAL CONDUCTED UNDER THE SUNSHINE PROJECT SAFETY NET GRANT FOR REIMBURSABLE MEDICAL EXPENSES NOT COVERED BY INSURANCE 12 12317 FMV X X 0 0 0 0 0 0 0 0 0 DAVID FRAZER CEO 191783 0 18594 0 0 0 0 0 0 0 210377 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE BOARD OF DIRECTORS RECEIVES THE DRAFT OF THE FORM 990 AND APPROVES THE FORM 990 PRIOR TO THE FORM BEING FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE FOUNDATION'S CONFLICT OF INTEREST POLICY IS DISCUSSED AT ORIENTATION OF OFFICERS AND DIRECTORS ON A PERIODIC BASIS, AT LEAST ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION FOR THE CEO AND OTHER KEY EMPLOYEES IS REVIEWED AND APPROVED BY THE EXECUTIVE COMMITTEE AND BOARD OF DIRECTORS. FORM 990, PART VI, SECTION C, LINE 19 THE NATIONAL PEDIATRIC CANCER FOUNDATION MAKES ITS GOVERNING DOCUMENTS, PRIVACY POLICY AND FINANCIAL INFORMATION AVAILABLE FOR PUBLIC INSPECTION THROUGH THE ORGANIZATION'S WEBSITE AS WELL AS UPON REQUEST. FORM 990, PART XII, LINE 2C, FINANCIAL STATEMENTS AND REPORTING THE PROCESS FOR OVERSIGHT OF THE AUDIT AND SELECTION OF AN INDEPENDENT ACCOUNTANT HAS NOT CHANGED FROM THE PRIOR YEAR.